Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Research & Development (2016 - 2025)

Historic Research & Development for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $3.3 million.

  • Lineage Cell Therapeutics' Research & Development rose 315.36% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year decrease of 31.65%. This contributed to the annual value of $12.5 million for FY2024, which is 2058.58% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Research & Development of $3.3 million as of Q3 2025, which was up 315.36% from $3.1 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Research & Development's 5-year high stood at $24.8 million during Q4 2021, with a 5-year trough of $2.8 million in Q3 2021.
  • For the 5-year period, Lineage Cell Therapeutics' Research & Development averaged around $4.5 million, with its median value being $3.3 million (2022).
  • Per our database at Business Quant, Lineage Cell Therapeutics' Research & Development skyrocketed by 85044.11% in 2021 and then tumbled by 8343.69% in 2022.
  • Lineage Cell Therapeutics' Research & Development (Quarter) stood at $24.8 million in 2021, then tumbled by 83.44% to $4.1 million in 2022, then decreased by 4.82% to $3.9 million in 2023, then fell by 12.37% to $3.4 million in 2024, then fell by 4.44% to $3.3 million in 2025.
  • Its Research & Development stands at $3.3 million for Q3 2025, versus $3.1 million for Q2 2025 and $3.1 million for Q1 2025.